A Prospective Randomized Study Comparing Total Neoadjuvant Treatment Followed by Total Mesorectal Excision (TME) and Conventional Long Course Chemoradiotherapy Followed By TME And Adjuvant Chemotherapy in Locally Advanced Rectal Cancer - ReCTON Trial

KIDWAI MEMORIAL INSTITUTE OF ONCOLOGY0 个研究点目标入组 0 人开始时间: 待定最近更新: 2022年10月17日

试验速览

暂无简介。

•1. Age between 18 to 75 years
•2. Newly diagnosed locally advanced primary resectable rectal adenocarcinoma on biopsy without distant metastases
•3. Lower border of tumour Ã¢â?°Â¤ 15 cm from Anal Verge
•4. High risk features on MRI: any one of below
•T3 anyN M0, T4 any N M0, anyT N1+ M0, Threatened CRM, MRF involvement, Extramural vascular invasion
•5. Eastern Cooperative Oncology Group (ECOG) performance score of 0Ã¢â?¬â??2
•6. Written informed consent

•1. Extensive tumor growth leading to primarily unresectable eg. Tumor involving lumbosacral nerve root, tumor involving lateral pelvic wall, tumor involving sacrum S3 and above
•2. Recurrent rectal cancer
•3. Partially treated patients
•4. FAP or HNPCC, Active CrohnÃ¢â?¬•s disease or ulcerative colitis
•5. Concomitant malignancy
•6. History of peripheral neuropathy
•7. History of Cardiac disease / Stroke
•8. Chronic kidney disease
•9. Chronic liver disease with bilirubin more than 2 mg/dl
•10. Pregnant or breast-feeding women

发起方